跳转至内容
Merck
CN
  • Hydroquinone-salicylic acid conjugates as novel anti-melasma actives show superior skin targeting compared to the parent drugs.

Hydroquinone-salicylic acid conjugates as novel anti-melasma actives show superior skin targeting compared to the parent drugs.

Journal of dermatological science (2014-09-23)
Pei-Wen Hsieh, Ibrahim A Aljuffali, Chia-Lang Fang, Shu-Hao Chang, Jia-You Fang
摘要

Hydroquinone (HQ) and salicylic acid (SA) are drugs for treating melasma through the mechanisms of tyrosinase inhibition and chemical peeling, respectively. Their high frequency of causing skin irritation has led to limited use of both drugs. We designed the new conjugates obtained by joining HQ and SA by the co-drug concept for evaluating cutaneous absorption capability. Monoester (4-hydroxyphenyl 2-hydroxybenzoate, HPH) and diester (1,4-phenylene bis(2-hydroxybenzoate), PBH) forms of the conjugates were synthesized and physicochemically characterized. The enzymatic hydrolysis to the parent drugs was examined. Both an equimolar dose and a saturated solubility were utilized as the applied dose for testing cutaneous absorption via pig and nude mouse skins. The conjugates had higher lipophilicity, less aqueous solubility, and a lower melting point/crystallinity than the parent drugs. Both conjugates showed a quick conversion into the parent drugs in esterases and skin homogenates, with PBH showing the greater hydrolysis. The hydrolysis level in skin after topical application was less as compared to that in esterases and homogenates. The tyrosinase inhibition (%) and molecular docking demonstrated that the conjugates possessed skin-lightening capability (3% for HPH and 7% for PBH) although this activity was lower than that of HQ (23%). The conjugates showed an increased skin deposition compared to the respective parent drugs. Total absorption of HPH and PBH led to a 13- and 19-fold enhancement in cutaneous retention compared to HQ alone. A similar increment of skin deposition was shown for the conjugates when compared to SA. Contrary to skin reservoir retention, transdermal transport across the skin was decreased by the conjugates, especially for PBH. This indicates the maximization of cutaneous targeting by the conjugates. Topically applied HPH and PBH can be the new candidates for treating melasma due to efficient skin absorption and acceptable skin tolerance.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
四氢呋喃, inhibitor-free, suitable for HPLC, ≥99.9%
Sigma-Aldrich
四氢呋喃, contains 200-400 ppm BHT as inhibitor, ACS reagent, ≥99.0%
Sigma-Aldrich
四氢呋喃, anhydrous, ≥99.9%, inhibitor-free
Sigma-Aldrich
四氢呋喃, anhydrous, contains 250 ppm BHT as inhibitor, ≥99.9%
Sigma-Aldrich
4-(二甲氨基)吡啶, ReagentPlus®, ≥99%
Sigma-Aldrich
四氢呋喃, ≥99.0%, contains 200-400 ppm BHT as inhibitor, ReagentPlus®
Sigma-Aldrich
四氢呋喃, contains 250 ppm BHT as inhibitor, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.9%
Sigma-Aldrich
L-赖氨酸 单盐酸盐, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
四氢呋喃, ACS reagent, ≥99.0%, contains 200-400 ppm BHT as inhibitor
Sigma-Aldrich
L-赖氨酸 单盐酸盐, reagent grade, ≥98% (HPLC)
Supelco
L-赖氨酸 单盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
四氢呋喃, analytical standard
Supelco
四氢呋喃, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
4-(二甲氨基)吡啶, purum, ≥98.0% (NT)
Sigma-Aldrich
L-赖氨酸 单盐酸盐, BioUltra, ≥99.5% (AT)
Supelco
四氢呋喃, Selectophore, ≥99.5%
赖氨酸 盐酸盐, European Pharmacopoeia (EP) Reference Standard
Supelco
L-赖氨酸 单盐酸盐, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
L-赖氨酸盐酸盐 溶液, 100 mM amino acid in 0.1 M HCl, analytical standard
USP
4-(二甲氨基)吡啶, United States Pharmacopeia (USP) Reference Standard
伐昔洛韦杂质G, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
四氢呋喃, inhibitor-free, purification grade